Lv5
1003 积分 2021-08-11 加入
Assessing first-line treatment for advanced EGFR-mutated NSCLC in diverse clinicopathological subgroups: a systematic review and network meta-analysis
3天前
已完结
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
3天前
已完结
YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non–Small Cell Lung Cancer
3天前
已完结
Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer
3天前
已完结
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC
3天前
已完结
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
3天前
已完结
MET Enhances Amivantamab Binding to EGFR and Antibody‐Dependent Cellular Toxicity
3天前
已完结
Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer
4天前
已完结
Prognostic Impact of Bulky Lymph Node Metastasis in Thoracic Esophageal Squamous Cell Carcinoma: A Multicenter Cohort Study
8天前
已完结
Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis
9天前
已完结
皖公网安备34019202002308
